Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTX NASDAQ:JANX NASDAQ:SANA NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.16$2.62$0.49▼$3.62$198.46M1.57818,136 shs565,964 shsJANXJanux Therapeutics$13.89$14.42$12.12▼$35.34$847.01M2.58956,866 shs737,321 shsSANASana Biotechnology$3.07$3.26$1.63▼$6.55$854.36M2.173.97 million shs3.70 million shsSPRYARS Pharmaceuticals$7.43$8.30$6.66▼$18.90$737.80M0.931.93 million shs3.67 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics0.00%-9.24%-11.11%-6.09%+203.46%JANXJanux Therapeutics0.00%-2.05%-12.20%+5.71%-42.79%SANASana Biotechnology0.00%-12.54%-12.78%-20.26%+75.93%SPRYARS Pharmaceuticals0.00%-14.99%-9.17%-16.05%-45.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.16$2.62$0.49▼$3.62$198.46M1.57818,136 shs565,964 shsJANXJanux Therapeutics$13.89$14.42$12.12▼$35.34$847.01M2.58956,866 shs737,321 shsSANASana Biotechnology$3.07$3.26$1.63▼$6.55$854.36M2.173.97 million shs3.70 million shsSPRYARS Pharmaceuticals$7.43$8.30$6.66▼$18.90$737.80M0.931.93 million shs3.67 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics0.00%-9.24%-11.11%-6.09%+203.46%JANXJanux Therapeutics0.00%-2.05%-12.20%+5.71%-42.79%SANASana Biotechnology0.00%-12.54%-12.78%-20.26%+75.93%SPRYARS Pharmaceuticals0.00%-14.99%-9.17%-16.05%-45.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics 2.88Moderate Buy$6.60205.56% UpsideJANXJanux Therapeutics 2.60Moderate Buy$45.85230.07% UpsideSANASana Biotechnology 2.67Moderate Buy$9.50209.45% UpsideSPRYARS Pharmaceuticals 2.40Hold$28.25280.22% UpsideCurrent Analyst Ratings BreakdownLatest CNTX, SANA, JANX, and SPRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026JANXJanux Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$22.005/11/2026SANASana Biotechnology Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.005/8/2026JANXJanux Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $26.005/8/2026JANXJanux Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $36.005/8/2026JANXJanux Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$68.00 ➝ $58.005/4/2026JANXJanux Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/1/2026SANASana Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/28/2026JANXJanux Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $28.004/24/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/22/2026JANXJanux Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/AJANXJanux Therapeutics$10M84.70N/AN/A$15.91 per share0.87SANASana BiotechnologyN/AN/AN/AN/A$0.60 per shareN/ASPRYARS Pharmaceuticals$84.28M8.75N/AN/A$1.16 per share6.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)JANXJanux Therapeutics-$113.62M-$1.84N/AN/AN/AN/A-12.93%-12.23%8/6/2026 (Estimated)SANASana Biotechnology-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%N/ASPRYARS Pharmaceuticals-$171.30M-$1.75N/AN/AN/A-200.00%-130.75%-58.58%N/ALatest CNTX, SANA, JANX, and SPRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026SPRYARS Pharmaceuticals-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million5/11/2026Q1 2026SANASana Biotechnology-$0.15-$0.14+$0.01-$0.17N/AN/A5/7/2026Q1 2026JANXJanux Therapeutics-$0.5202-$0.39+$0.1302-$0.39$4.36 million$3.73 million5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/23/2026Q4 2025CNTXContext Therapeutics-$0.11-$0.14-$0.03-$0.14N/AN/A3/9/2026Q4 2025SPRYARS Pharmaceuticals-$0.42-$0.42N/A-$0.42$25.58 million$28.09 million3/3/2026Q4 2025SANASana Biotechnology-$0.13-$0.16-$0.03-$0.21N/AN/A2/26/2026Q4 2025JANXJanux Therapeutics-$0.65-$0.51+$0.14-$0.51$0.08 million$7.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A8.968.96JANXJanux TherapeuticsN/A17.0117.01SANASana BiotechnologyN/A1.291.29SPRYARS Pharmaceuticals1.477.287.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%JANXJanux Therapeutics75.39%SANASana Biotechnology88.23%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics4.80%JANXJanux Therapeutics7.90%SANASana Biotechnology25.40%SPRYARS Pharmaceuticals33.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableJANXJanux Therapeutics3060.98 million56.17 millionOptionableSANASana Biotechnology380278.29 million207.61 millionOptionableSPRYARS Pharmaceuticals9099.30 million65.74 millionOptionableCNTX, SANA, JANX, and SPRY HeadlinesRecent News About These CompaniesArs Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access programMay 16 at 8:53 AM | seekingalpha.comARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...May 16 at 8:53 AM | finance.yahoo.comARS Pharmaceuticals (NASDAQ:SPRY) Upgraded by Wall Street Zen to Sell RatingMay 16 at 2:26 AM | americanbankingnews.comARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call TranscriptMay 15 at 10:00 PM | seekingalpha.comARS Pharmaceuticals Q1 Earnings Call HighlightsMay 15 at 12:08 PM | marketbeat.comARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue EstimatesMay 15 at 8:12 AM | zacks.comARS Pharmaceuticals Reports Q1 2026 Financial Results Highlighting $22.7 Million in Revenue and Progress on neffy® CommercializationMay 15 at 6:30 AM | quiverquant.comQARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate UpdateMay 15 at 6:00 AM | globenewswire.comARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsMay 15 at 2:31 AM | benzinga.comARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsMay 15 at 2:08 AM | benzinga.comARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as PresidentMay 13, 2026 | globenewswire.comUBS Group AG Purchases 1,550,980 Shares of ARS Pharmaceuticals, Inc. $SPRYMay 11, 2026 | marketbeat.comContrasting ARS Pharmaceuticals (NASDAQ:SPRY) & Critical Outcome Technologies (OTCMKTS:COTQF)May 11, 2026 | americanbankingnews.comInvestment Management Associates Inc. ADV Makes New $3.63 Million Investment in ARS Pharmaceuticals, Inc. $SPRYMay 9, 2026 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $28.25 Average PT from BrokeragesMay 9, 2026 | americanbankingnews.comARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comEarnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to DeclineMay 6, 2026 | zacks.comARS Pharmaceuticals (SPRY) Projected to Post Quarterly Earnings on WednesdayMay 6, 2026 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Hold" by BrokeragesMay 4, 2026 | marketbeat.comHow The ARS Pharmaceuticals (SPRY) Narrative Is Shifting With Fresh Analyst Models And ApprovalsMay 2, 2026 | finance.yahoo.comARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?April 23, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Avis Short Squeeze Shocked the Market: Are These 3 Stocks Next?By Dan Schmidt | April 27, 2026CNTX, SANA, JANX, and SPRY Company DescriptionsContext Therapeutics NASDAQ:CNTX$2.16 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$2.19 +0.03 (+1.44%) As of 07:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Janux Therapeutics NASDAQ:JANX$13.89 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$13.97 +0.08 (+0.57%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Sana Biotechnology NASDAQ:SANA$3.07 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$3.05 -0.02 (-0.65%) As of 07:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.ARS Pharmaceuticals NASDAQ:SPRY$7.43 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$7.35 -0.08 (-1.08%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
